| Date | Title | | | 07/29/10 | Isis Earns $5 Million Milestone Payment From GSK for Designation of a Development Candidate to Treat an Undisclosed Rare and Serious Disease| CARLSBAD, Calif., July 29, 2010 /PRNewswire via COMTEX/ --Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it has earned a $5 million milestone payment from GlaxoSmithKline (NYSE: GSK) related to the designation as a development candidate of a drug to treat an undisclosed rare and serious disease. Isis will develop the drug to Phase 2 proof-of-concept, at which time GSK has the option to license it.
"We are pleased to have achieved this milestone so early in our collaboration... |
|  | | 07/26/10 | Webcast Alert: Isis Pharmaceuticals' Second Quarter 2010 Financial Results Conference Call| CARLSBAD, Calif., July 26, 2010 /PRNewswire via COMTEX/ --Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:
What: Isis Pharmaceuticals' Second Quarter 2010 Financial Results
When: Monday, August 9, 2010 at 8:30 a.m. ET / 5:30 a.m. PT
Where: www.isispharm.com
How: Live on the Internet. Simply log onto our Web site
listed above.
Contacts: Kristina Lemonidis
Director, Investor Relations
... |
| | | 06/29/10 | Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions| ORLANDO, Fla. and CARLSBAD, Calif., June 29 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq:ISIS - News) announced today that data from seven programs in Isis' broad metabolic disease franchise were presented at the American Diabetes Association's (ADA) 70th Scientific Sessions in Orlando. These presentations included two oral talks highlighting data from Isis' Phase 2 study of ISIS 113715 in patients with type 2 diabetes and Isis' Phase 1 study of ISIS-GCGRRx. Isis and collab... |
| | | 06/22/10 | Isis and Alnylam Provide Update on Regulus' Strategic Alliance with Sanofi-Aventis| Press Release Source: Alnylam Pharmaceuticals, Inc. On Tuesday June 22, 2010, 6:05 am
CAMBRIDGE, Mass. and CARLSBAD, Calif.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News):
New Partnership Validates Alnylam and Isis Strategy for Shareholder Value Creation
Regulus, Alnylam and Isis to Host Conference Call Webcast to Discuss Regulus-Sanofi-aventis Collaboration on June 22, 2010 at 8:30 a.m. ET (5:30 a.m. PT)
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News) and Is... |
| | | 06/22/10 | Sanofi-Aventis and Regulus Therapeutics Form Major Strategic Alliance on microRNA Therapeutics| - Largest microRNA therapeutics alliance to date, valued at
potentially over $750 million including a $25 million upfront, a $10
million future equity investment subject to mutual agreement on company
valuation, and a three-year option worth $50 million for a broader
technology alliance -
- Focused on developing microRNA-based medicines toward four targets -
- Structured as multi-year collaboration intended to advance several
investigational new drugs in... |
| | | 06/16/10 | Isis Pharmaceuticals to Present at The Wells Fargo 2010 Healthcare Conference| CARLSBAD, Calif., June 16, 2010 /PRNewswire via COMTEX/ --Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Wells Fargo's 2010 Healthcare Conference on Wednesday, June 23, 2010 at 2:00 p.m. ET at the InterContinental Boston.
A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the presentation ... |
| | | 06/15/10 | Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17| CARLSBAD, Calif., June 15, 2010 /PRNewswire via COMTEX/ --Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it will conduct the fourth and last of this series of conference calls focused on the drugs in Isis' development pipeline. The last call of the series will focus on Isis' neurodegenerative franchise and will be held on Thursday, June 17, 2010 at 12:00 p.m. ET. This call will be archived for a limited time on Isis' Web site.
Isis has conducted three earlier calls that high... |
| | | 06/11/10 | Isis Pharmaceuticals to Present at The Goldman Sachs 31st Annual Global Healthcare Conference| CARLSBAD, Calif., June 11, 2010 /PRNewswire via COMTEX/ --Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Goldman Sachs' 31st Annual Global Healthcare Conference on Tuesday, June 15, 2010 at 8:35 a.m. PT at the Century Plaza Hyatt Regency in Los Angeles.
A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com... |
| | | 06/04/10 | Isis Pharmaceuticals to Present Company Overview| CARLSBAD, Calif., June 4, 2010 /PRNewswire via COMTEX/ --Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the:
Jefferies 2010 Global Life Sciences Conference on Tuesday, June 8, 2010 at 2:30 p.m. ET at The Grand Hyatt in New York
Morgan Joseph 2010 Best Ideas Conference on Wednesday, June 9, 2010 at 3:30 p.m. ET at Millennium Broadway Hotel in New York
Needham 9th Annual Heal... |
| | | 05/26/10 | Isis Pharmaceuticals to Present a General Corporate Update at Its 2010 Annual Meeting of Stockholders and Open House| CARLSBAD, Calif., May 26, 2010 /PRNewswire via COMTEX/ --Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a general corporate update in conjunction with its 2010 Annual Meeting of Stockholders and Open House on June 2 from 2:00 p.m. to 6:00 p.m. Pacific Time in Carlsbad, CA.
The agenda for the meeting is as follows:
2:00 p.m. - 2:15 p.m. Annual Meeting of Stockholders (stockholders of record as of April 6, 2010 on... |
| | | 05/21/10 | Isis Pharmaceuticals to Present at the 2010 Citi Investment Research Global Health Care Conference| CARLSBAD, Calif., May 21, 2010 /PRNewswire via COMTEX/ --Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Citi Investment Research's 2010 Global Health Care Conference on Thursday, May 27, 2010 at 2:30 p.m. ET at the New York Hilton Hotel.
A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of t... |
| | | 05/17/10 | Isis Pharmaceuticals to Discuss Its Cancer Franchise in a Conference Call on Wednesday, May 19| CARLSBAD, Calif., May 17, 2010 /PRNewswire via COMTEX/ --Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it will conduct the third of its series of four conference calls focused on the drugs in Isis' development pipeline. The third call of the series will focus on Isis' cancer franchise and will be held on Wednesday, May 19, 2010 at 12:00 p.m. ET.
Each of the calls highlights a different therapeutic franchise and provides higher-level strategic insight into target selection, d... |
| | | 05/06/10 | Isis Reports Financial Results and Highlights for First Quarter 2010| Conference Call Webcast Thursday, May 6, 8:30 a.m. ET at www.isispharm.com
CARLSBAD, Calif., May 6, 2010 /PRNewswire via COMTEX/ --Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the quarter ended March 31, 2010. The Company finished the first quarter of 2010 with a pro forma net operating loss (NOL) of $1.5 million compared to pro forma net operating income of $2.1 million in the first quarter of 2009. On a GAAP basis, Isis reported a net operating loss ... |
| | | 04/29/10 | Webcast Alert: Isis Pharmaceuticals' First Quarter 2010 Financial Results Conference Call| CARLSBAD, Calif., April 29, 2010 /PRNewswire via COMTEX/ --Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:
What: Isis Pharmaceuticals' First Quarter 2010 Financial Results
When: Thursday, May 6, 2010 at 8:30 a.m. ET / 5:30 a.m. PT
Where: www.isispharm.com
How: Live on the Internet. Simply log onto our Web site
listed above.
Contacts: Kristina Lemonidis
Director, Investor Relat... |
| | | 04/26/10 | Isis Pharmaceuticals to Discuss Its Metabolic Franchise in a Conference Call on Wednesday, April 28| CARLSBAD, Calif., April 26, 2010 /PRNewswire via COMTEX/ --Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it will conduct the second of its series of four conference calls focused on the drugs in Isis' development pipeline. The second call of the series will focus on Isis' metabolic franchise and will be held on Wednesday, April 28, 2010 at 12:00 p.m. ET. This call will be archived for a limited time on Isis' Web site.
Each of the four calls will highlight a different therap... |
| | | 04/12/10 | Isis Pharmaceuticals to Discuss Its Cardiovascular Franchise in a Conference Call on Wednesday, April 14| CARLSBAD, Calif., April 12, 2010 /PRNewswire via COMTEX/ --Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it will conduct a series of four conference calls focused on the drugs in Isis' development pipeline. The first call of the series will focus on Isis' cardiovascular franchise and will be held on Wednesday, April 14, 2010 at 12:00 p.m. ET. This call will be archived for a limited time on Isis' Web site.
Each of the four calls will highlight a different therapeutic franch... |
| | | 03/31/10 | GSK and Isis Pharmaceuticals Collaborate on RNA Therapeutics for Rare and Infectious Diseases| -
GSK has right to license and commercialize compounds at clinical proof-of-concept
Isis gives GSK access to expertise in discovery and development of anti-RNA therapeutics
CARLSBAD, Calif. and LONDON, March 31, 2010 /PRNewswire via COMTEX/ --GlaxoSmithKline (NYSE: GSK) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today a new strategic alliance that will apply the Isis antisense drug discovery platform to seek out and develop new therapeutics against targets for rare and serious... |
| | | 03/17/10 | Isis Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference| CARLSBAD, Calif., March 17, 2010 /PRNewswire via COMTEX/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Barclays' 2010 Global Healthcare Conference on Tuesday, March 23, 2010 at 3:45 p.m. ET at Loews Miami Hotel.
A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be ... |
| | | 03/15/10 | Mipomersen Phase 3 Study in HoFH Patients Featured in The Lancet| CAMBRIDGE, Mass. & CARLSBAD, Calif., Mar 15, 2010 (BUSINESS WIRE) -- Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) today announced that data from a phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were published in The Lancet. This study met its primary endpoint, resulting in an average LDL-C reduction of greater than 100 mg/dL in this very high-risk patient population.
"Currently available treatments do not provide adequa... |
| | | 03/08/10 | Isis Earns $6 Million Milestone Payment From Bristol-Myers Squibb for BMS-PCSK9Rx| CARLSBAD, Calif., March 8, 2010 /PRNewswire via COMTEX/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it has earned a $6 million milestone payment from Bristol-Myers Squibb Company (NYSE: BMY) related to the acceptance of initial regulatory filings to begin Phase 1 clinical studies for BMS-PCSK9Rx. BMS-PCSK9Rx is an antisense drug that arose out of the ongoing collaboration between Bristol-Myers Squibb and Isis to identify antisense drugs targeting PCSK9 to lower low-density ... |
| | | 03/05/10 | ISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS| Isis' first drug to treat neurodegenerative disease enters clinical trialsCARLSBAD, Calif., March 5, 2010 /PRNewswire via COMTEX/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it has initiated a Phase 1 study of ISIS-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig's disease also known as familial amyotrophic lateral sclerosis (ALS). Approximately 20 percent of all familial ALS cases are caused by a mutant form of superoxide dismutase, or SOD1. ISIS-SOD1R... |
| | | 03/02/10 | Isis Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference| CARLSBAD, Calif., March 2, 2010 /PRNewswire via COMTEX/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Cowen's 30th Annual Health Care Conference on Monday, March 8, 2010 at 2:30 p.m. ET at The Boston Marriott Copley Place.
A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the presentati... |
| | | 03/01/10 | Isis Reports Strong Financial Results and Highlights for 2009|
Reports Second Consecutive Year of Pro Forma Net Income
Achieves All 2009 Financial Guidance Metrics
Conference Call Webcast Monday, March 1, 8:30 a.m. EST at www.isispharm.com
CARLSBAD, Calif., March 1, 2010 /PRNewswire via COMTEX/ -- Reports Second Consecutive Year of Pro Forma Net Income Achieves All 2009 Financial Guidance MetricsConference Call Webcast Monday, March 1, 8:30 a.m. EST at www.isispharm.com
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2009 financial... |
| | | 02/23/10 | Webcast Alert: Isis Pharmaceuticals' 2009 Financial Results and Highlights Conference Call| CARLSBAD, Calif., Feb 23, 2010 /PRNewswire via COMTEX/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:
What: Isis Pharmaceuticals' 2009 Financial Results and Highlights
When: Monday, March 1, 2010 at 8:30 a.m. ET / 5:30 a.m. PT
Where: www.isispharm.com
How: Live on the Internet. Simply log onto our Web site listed above.
If you are unable to participate during the live event, a replay of the webcast will be available for ... |
| | | 02/10/10 | Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint| 28 Percent LDL-C Reduction in High-Risk Patient Population
CAMBRIDGE, Mass. & CARLSBAD, Calif., Feb 10, 2010 (BUSINESS WIRE) -- Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent ... |
| | | 01/25/10 | Regulus, Alnylam and Isis Announce U.S. Allowance of Tuschl III Patent Application Covering miR-21| - miR-21 Patent Allowance Strengthens Regulus Leadershipin microRNA Therapeutic Drug Development -CARLSBAD, Calif. & CAMBRIDGE, Mass., Jan 25, 2010 (BUSINESS WIRE) -- Regulus Therapeutics Inc., Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in a patent application derived from the "Tuschl III" patent series that is assigned to Max Planck. The allowed claim... |
| | | 01/11/10 | Isis Pharmaceuticals Adds New Cardiovascular Drug to Development Pipeline| ISIS-APOCIIIRx to Treat HypertriglyceridemiaCARLSBAD, Calif., Jan 11, 2010 /PRNewswire via COMTEX/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it has added a new drug, ISIS-APOCIIIRx, to its development pipeline. ISIS-APOCIIIRx provides a novel approach to treat hypertriglyceridemia, or high levels of triglycerides (TG). Hypertriglyceridemia is an independent risk factor for cardiovascular disease. Hypertriglyceridemia is also a hallmark of metabolic syndrome, which occ... |
| | | 01/06/10 | Isis Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference| CARLSBAD, Calif., Jan 06, 2010 /PRNewswire via COMTEX/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at J.P. Morgan's 28th Annual Healthcare Conference on Wednesday, January 13, 2010, at 9:30 a.m. PT at the Westin St. Francis in San Francisco.
A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of... |
| |
|
